Compare BIIB & PAYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | PAYX |
|---|---|---|
| Founded | 1978 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5B | 35.2B |
| IPO Year | 1996 | 1995 |
| Metric | BIIB | PAYX |
|---|---|---|
| Price | $253.83 | $108.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 36 | 19 |
| Target Price | ★ $260.10 | $114.57 |
| AVG Volume (30 Days) | 1.2M | ★ 2.8M |
| Earning Date | 10-28-2026 | 12-18-2026 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | N/A | ★ 6.77 |
| EPS | ★ 2.66 | 1.21 |
| Revenue | ★ $9,890,600,000.00 | $6,512,000,000.00 |
| Revenue This Year | $6.17 | $5.41 |
| Revenue Next Year | $1.86 | $5.48 |
| P/E Ratio | $92.34 | ★ $89.54 |
| Revenue Growth | 2.22 | ★ 16.88 |
| 52 Week Low | $146.52 | $85.45 |
| 52 Week High | $258.78 | $127.98 |
| Indicator | BIIB | PAYX |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 46.37 |
| Support Level | $184.50 | $87.59 |
| Resistance Level | N/A | $126.21 |
| Average True Range (ATR) | 7.32 | 2.68 |
| MACD | 1.24 | 0.32 |
| Stochastic Oscillator | 77.58 | 29.69 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Paychex is a cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including professional employer organization, or PEO, offerings, enabling clients to reduce HR overhead. Paychex primarily targets small and midsize businesses, although its acquisition of Paycor in 2025 signals the firm's aspirations to expand into the midmarket segment, serving firms with more than 100 employees. As of fiscal 2026, Paychex has approximately 840,000 clients and manages payroll for one in 11 workers in the United States.